top of page

Clinical Statins: Acute Coronary Syndrome & Ischemic Stroke - #MEDSHED


 


 

🐔 Clinical Statins: ACS/AIS - #MEDSHED


Statins are a mainstay of therapy for stroke and heart attack secondary prevention. They work by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, stimulating LDL catabolism. Additionally, statins contain pleoitropic properties, such as improved endothelial function, reduced inflammation, inhibit platelet aggregation, and anticoagulant effects


Monitoring - Side Effects

Hepatotoxicity Increased serum transaminases (ALT > AST)

Most cases occur within 3 months/dose increase


Muscle-related Myalgia, myopathy, rhabdomyolysis

Highest risk within first year of use, dose increase, or interacting medications


Guideline LDL-C Targets Acute Coronary Syndrome (ACS) - secondary prevention

Target: 50% reduction AND < 50 mg/dL


Acute Ischemic Stroke (AIS) - secondary prevention

Target: < 70 mg/dL

Unknown benefit when LDL-C levels are already low at time of stroke


High-intensity rosuvastatin has been associated with more effectiveness in reducing LDL vs atorvastatin


Let me know what thoughts and questions you have in the comments!


PHARMWYZE SITREP Newsletter: https://www.pharmwyze.com/sitrepnewsl...


9 views0 comments

Comments


bottom of page